Market Overview - On July 23, the Shanghai Composite Index rose by 0.01%, while the Shenzhen Component Index fell by 0.37%, and the ChiNext Index remained unchanged [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.86 trillion yuan, with over 4,000 stocks declining [1] - Sectors such as hydropower, beauty care, securities insurance, CRO, banking, and small metals saw significant gains, while sectors like Hainan, military industry, ultra-high voltage, and cement experienced declines [1] Focus Stocks - Xue Ren Group experienced a trading halt, with the market's consecutive board height reduced to four for Nanmin Group [3] - Zhibo Design and Shen Shui Planning Institute both achieved a 20% increase for three consecutive boards in the hydropower station concept stocks [3] - Hengli Drilling Tools reached a 30% increase for three consecutive boards in the shield machine concept stocks, while China Railway Construction reached a 20% increase for three consecutive boards [3] Top Net Buy and Sell on Dragon and Tiger List - The top three net buying stocks were Xue Ren Group (244 million yuan), Kailong Co., Ltd. (134 million yuan), and Qingyun Technology (97.91 million yuan) [4] - The top three net selling stocks were Tianshan Co., Ltd. (295 million yuan), China Power Construction (220 million yuan), and Lansheng Co., Ltd. (150 million yuan) [5] - Xue Ren Group's stock surged, with a turnover rate of 32.19% and a trading volume of 2.372 billion yuan, with net buying from the Shenzhen Stock Connect of 164 million yuan [5] Company Developments - Xue Ren Group has developed a comprehensive technical plan for large-scale concrete temperature control needs in its projects and has participated in multiple hydropower projects in the Yarlung Tsangpo River basin [8] - The company’s helium compressor is used in a major national scientific research project, achieving international leading technology in the controlled nuclear fusion field [8] - Xue Ren Group is investing 280 million yuan to build a hydrogen fuel cell system production base, expected to be operational by July 2028, aligning with national hydrogen energy policies [8] Other Notable Stocks - Nanjing New Hundred, involved in innovative drugs and cell immunotherapy, reported a revenue increase of 1.98% to 6.7 billion yuan in 2024 [11] - Zhendong Pharmaceutical, focusing on anti-tumor traditional Chinese medicine, has a leading product in the market and has resolved a significant arbitration issue [15] - Tianshan Co., Ltd. saw a decline of 6.27% with a trading volume of 1.371 billion yuan, while Shangfeng Cement fell by 9.27% with a trading volume of 675 million yuan [12][18]

Group 1 - The cell immunotherapy concept index rose by 0.56%, ranking fourth among concept sectors, with 25 stocks increasing in value [1] - Notable gainers included Nanjing Xinbai, Saily Medical, and *ST Biology, which reached their daily limit up, with increases of 8.61%, 7.86%, and 7.18% respectively [1] - The largest declines were seen in Chengda Pharmaceutical, Hainan Haiyao, and Jiuzhitang, with decreases of 13.12%, 6.31%, and 5.07% respectively [1] Group 2 - The cell immunotherapy sector experienced a net outflow of 213 million yuan in main funds, with 27 stocks seeing net inflows [2] - Saily Medical led the net inflow with 336 million yuan, followed by Zhaoyan New Drug, Nanjing Xinbai, and Northeast Pharmaceutical with net inflows of 203 million yuan, 111 million yuan, and 77.41 million yuan respectively [2] - The net inflow ratios for Nanjing Xinbai, Saily Medical, and Zhaoyan New Drug were 43.57%, 21.82%, and 12.72% respectively [3] Group 3 - The cell immunotherapy sector's performance was highlighted by the significant trading volumes and turnover rates of leading stocks, indicating strong investor interest [3][4] - Stocks like Saily Medical and Nanjing Xinbai showed high turnover rates of 28.92% and 2.96% respectively, reflecting active trading [3] - The overall market sentiment in the cell immunotherapy sector remains positive despite some individual stock declines [2][6]

Core Viewpoint - The gene sequencing sector has shown a modest increase of 0.44%, ranking fifth among concept sectors, with notable performances from stocks like Nanjing Xinbai and Zhaoyan New Drug [1][2]. Market Performance - The gene sequencing concept saw 29 stocks rise, with Nanjing Xinbai hitting the daily limit up, and other top gainers including Heyuan Biological and Qianyuan Pharmaceutical, which rose by 8.61%, 6.96%, and 6.43% respectively [1]. - Conversely, stocks like Puni Testing, Zhongyuan Co., and Betta Pharmaceuticals experienced declines of 3.73%, 2.71%, and 2.46% respectively [1]. Capital Flow - The gene sequencing sector attracted a net inflow of 122 million yuan, with 34 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - Zhaoyan New Drug led the sector with a net inflow of 203 million yuan, followed by Nanjing Xinbai and Qianyuan Pharmaceutical with net inflows of 111 million yuan and 64.63 million yuan respectively [2]. Capital Inflow Ratios - Nanjing Xinbai, Zhaoyan New Drug, and Heyuan Biological had the highest net inflow ratios at 43.57%, 12.72%, and 10.88% respectively [3].

证券代码：600682 证券简称：南京新百 公告编号：临 2025-019 南京新街口百货商店股份有限公司 关于江苏证监局行政监管措施决定的 整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司或上市公司）、控股股东三 胞集团有限公司（以下简称三胞集团）于 2025 年 7 月 18 日分别收到中国证券监 督管理委员会江苏监管局（以下简称江苏证监局）下发的《关于对南京新百采取 责令改正措施并对袁亚非等相关责任人采取出具警示函措施的决定》（行政监管 措施[2025]102 号）、《江苏证监局关于对三胞集团有限公司及袁亚非采取出具警 示函措施的决定》（行政监管措施[2025]103 号）（以下统一简称《决定书》）、 要求上市公司和三胞集团就《决定书》中所指出的问题进行整改。 收到《决定书》后，公司高度重视，立即向全体董事、监事、高级管理人员及 相关部门人员进行通报、送达，并召集管理层、相关部门人员对《决定书》中涉 及的问题进行了全面梳理和针对性地分析讨论，同时根据相关法律法规、规范 ...

一、行政监管措施[2025]102号的主要内容 证券代码：600682 证券简称：南京新百 公告编号：临 2025-018 南京新街口百货商店股份有限公司 及控股股东收到江苏证监局 行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司或上市公司）、控股股 东三胞集团有限公司（以下简称三胞集团）于2025年7月18日分别收到中国证 券监督管理委员会江苏监管局（以下简称江苏证监局）下发的《关于对南京新 百采取责令改正措施并对袁亚非等相关责任人采取出具警示函措施的决定》（ 行政监管措施[2025]102号）、《江苏证监局关于对三胞集团有限公司及袁亚 非采取出具警示函措施的决定》（行政监管措施[2025]103号）（以下统一简 称《决定书》），现将有关情况公告如下： "南京新街口百货商店股份有限公司、袁亚非、杨怀珍、翟凌云、潘利建、 唐志清、钱静： 经查，南京新街口百货商店股份有限公司(以下简称南京新百或公司)存在 以下违规行为： 一、未及时审议及披露对外担保事项 南京 ...

Core Viewpoint - Nanjing Xinbai (600682) and its controlling shareholder, Sanpower Group, received an administrative regulatory decision from Jiangsu Securities Regulatory Bureau for violations related to the timely review and disclosure of external guarantee matters and the failure to disclose fund occupation issues involving the controlling shareholder and its related parties [1] Summary by Relevant Sections - Regulatory Actions - Jiangsu Securities Regulatory Bureau decided to impose corrective measures on Nanjing Xinbai and issued warning letters to responsible individuals [1] - Sanpower Group and Yuan Yafei will face similar regulatory measures [1] - Compliance and Governance - The company and related personnel have submitted a written rectification report and will enhance the study of laws and regulations to improve corporate governance [1]

Core Viewpoint - The company announced a cash dividend distribution of 0.016 CNY per share (including tax) to its shareholders, totaling approximately 21.43 million CNY [1][2][3] Dividend Distribution Plan - The profit distribution plan was approved at the annual general meeting on May 21, 2025, with a total share capital of 1,346,132,221 shares, excluding 7,000,000 shares held in the company's repurchase account [2][3] - The cash dividend will be distributed based on the adjusted total share capital, resulting in a total cash dividend payout of 21,426,115.54 CNY (including tax) [2][3] Relevant Dates - The record date for shareholders is July 15, 2025, with the last trading day on July 16, 2025, and the ex-dividend date also on July 16, 2025 [3][4] Implementation of Distribution - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch to all registered shareholders as of the record date [4][5] - Shareholders who have not completed designated trading will have their dividends held by the company until the trading is completed [4][5] Taxation Policies - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, while those holding for one year or less will have taxes calculated upon stock transfer [5][6] - For foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.0144 CNY per share [6][7]

Core Viewpoint - The legal opinion letter from Jiangsu Taihe Law Firm confirms the legality and compliance of Nanjing Xinjiekou Department Store Co., Ltd.'s differentiated equity distribution for the 2024 profit distribution plan, ensuring it aligns with relevant laws and regulations [3][11]. Group 1: Legal Framework and Compliance - The legal opinion is based on various laws including the Company Law, Securities Law, and specific regulations regarding share repurchase and equity distribution [3][4]. - The law firm conducted thorough verification and due diligence to ensure the accuracy and completeness of the facts presented in the legal opinion [4][5]. - The opinion is strictly for the purpose of the differentiated equity distribution and cannot be used for other purposes without prior written consent from the law firm [4][5]. Group 2: Differentiated Equity Distribution Details - The reason for the differentiated equity distribution is linked to the company's share repurchase plan, which involved repurchasing 7,000,000 shares, accounting for 0.52% of the total share capital [5][6]. - The profit distribution plan for 2024 proposes a cash dividend of RMB 0.16 per 10 shares, totaling RMB 21,426,115.54 (including tax) to be distributed among shareholders [7][8]. - The actual number of shares participating in the distribution is 1,339,132,221 after excluding the repurchased shares [8]. Group 3: Calculation and Impact - The cash dividend per share is calculated to be approximately RMB 0.0159 based on the total shares participating in the distribution [8][9]. - The impact of the differentiated equity distribution on the ex-rights and ex-dividend reference price is minimal, calculated to be less than 1% [9][10]. - The legal opinion concludes that the differentiated equity distribution complies with all relevant regulations and does not harm the interests of the company or its shareholders [10][11].

江苏泰和律师事务所 关于南京新街口百货商店股份有限公司 2024 年度差异化权益分派特殊除权除息事项的 专项法律意见书 泰和律师事务所 法律意见书 法律意见书 本所律师依据本法律意见书出具日为止的中国现行有效的法律、法规和规范 性文件，以及对南京新百差异化权益分派所涉及的有关事实的了解发表法律意 见。本法律意见书仅对南京新百 2024 年度利润分配所涉及的差异化权益分派相 关法律事项的合法合规性发表意见，不对有关会计、审计、验资等专业事项发表 意见。 本法律意见书仅供南京新百 2024 年度利润分配所涉及的差异化权益分派相 1 法律意见书 关法律事项之目的而使用，非经本所事先书面许可，不得用于其他任何目的。 本所同意将本法律意见书作为南京新百本次差异化权益分派的必备法律文 件之一，随其他申请材料一起上报或公开披露，并依法对出具的法律意见书承担 相应的法律责任。 江苏泰和律师事务所 关于南京新街口百货商店股份有限公司 2024 年度差异化权益分派特殊除权除息事项的 专项法律意见书 致：南京新街口百货商店股份有限公司 江苏泰和律师事务所（以下简称"本所"）接受南京新街口百货商店股份有限 公司(以下简称"南京新百" ...

南京新街口百货商店股份有限公司 证券代码：600682 证券简称：南京新百 公告编号：2025-017 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.016元（含税）。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/15 | － | 2025/7/16 | 2025/7/16 | 差异化分红送转： 是 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章及其他规范性文件，公 司回购专用账户中的股份，不享有股东大会表决权、利润分配、公积金转增股本、认购新股 ...